Thierrée Sarah, Richa Sami, Brunet Alain, Egreteau Laurine, Roig Quentin, Clarys David, El-Hage Wissam
UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.
No Lost Generation, Tours, France.
Eur J Psychotraumatol. 2020 Mar 3;11(1):1733248. doi: 10.1080/20008198.2020.1733248. eCollection 2020.
: There is a dearth of therapeutic solutions for traumatized young patients. Trauma reactivation conducted under the influence of the reconsolidation blocker propranolol (Reconsolidation Therapy) is a simple, cost-effective treatment option that has some promising initial results in adults suffering from posttraumatic stress disorder (PTSD). : To explore the usefulness of this novel treatment in children. The primary outcome was the reduction of PTSD symptoms at the end of treatment, while secondary outcomes included reduction in anxiety and in depressive symptoms. : An open-label clinical trial was conducted in a refugee camp in Syria, investigating the safety and efficacy of this therapeutic strategy in 117 children suffering from enduring PTSD symptoms. Participants received propranolol 90 minutes before briefly recalling (i.e. reactivating) a single personal traumatic memory, for 5 consecutive days. Self-reported anxiety, depressive, and PTSD symptoms were assessed at baseline, as well as 4 and 13 weeks after treatment. : A significant, clinically meaningful symptom reduction was observed at all post-treatment measurement times . baseline. More specifically, between baseline and the 13-week follow-up we observed a 64% PTSD symptoms reduction ( = 2.71). In a similar vein, we obtained a 39% symptoms reduction for depressive symptoms (1.01). The general anxiety symptoms improved, but eventually returned to prior level, probably because of the deteriorating living conditions in the camp. : This therapy appeared as a potentially safe and useful treatment strategy for children suffering from PTSD symptoms, warranting replication studies using stronger study designs. The social acceptability and ease of implementation of the treatment should also be noted.
对于受创伤的年轻患者而言，治疗方案匮乏。在再巩固阻滞剂普萘洛尔影响下进行的创伤再激活（再巩固疗法）是一种简单且经济高效的治疗选择，在患有创伤后应激障碍（PTSD）的成年人中已取得了一些颇具前景的初步成果。为探究这种新型治疗方法对儿童的有效性。主要结局指标是治疗结束时PTSD症状的减轻，次要结局指标包括焦虑和抑郁症状的减轻。在叙利亚的一个难民营中开展了一项开放标签临床试验，调查这种治疗策略对117名患有持续性PTSD症状儿童的安全性和有效性。参与者在短暂回忆（即再激活）单一个人创伤记忆前90分钟服用普萘洛尔，连续服用5天。在基线时以及治疗后4周和13周评估自我报告的焦虑、抑郁和PTSD症状。在所有治疗后测量时间均观察到症状有显著的、具有临床意义的减轻。与基线相比。更具体地说，在基线和13周随访之间，我们观察到PTSD症状减轻了64%（=2.71）。同样，我们观察到抑郁症状减轻了39%（=1.01）。一般焦虑症状有所改善，但最终又回到了先前水平，这可能是由于难民营生活条件恶化所致。这种疗法似乎是一种对患有PTSD症状儿童潜在安全且有用的治疗策略，值得采用更严格研究设计进行重复研究。还应注意该治疗方法的社会可接受性和实施的简便性。
